Jochen H. Lorch
Expertise in
19
conditions

Dr. Jochen H. Lorch

Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
31 Years of Experience
Expertise in
19
conditions
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jochen Lorch is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Lorch has been practicing medicine for over 31 years is highly rated in 19 conditions, according to our data. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Medullary Thyroid Carcinoma, Adenoid Cystic Carcinoma, and Thyroidectomy.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Regensburg, 1994
Residency
University of Pennsylvania Health System
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine - Medical Oncology (Certified)
Fellowships
McGaw Medical Center of Northwestern University
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 8 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Lorch has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer
A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Radiation, Procedure, Biological, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck
A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug, Radiation
Study Drugs: Buparlisib, Cisplatin
Study Phase: Phase 1
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drug: MLN0128
Study Phase: Phase 1/Phase 2
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Drug
Study Drug: DPX-E7 vaccine
Study Phase: Phase 1/Phase 2
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Biological
Study Drug: Epstein-Barr Virus Specific Immunotherapy
Study Phase: Phase 2
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

93 Total Publications

NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025.
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 10, 2025
Similar Doctors
Leo I. Gordon
Expertise in
32
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
32
conditions
Dr. Leo I. Gordon
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
52+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Gordon has been practicing medicine for over 52 years is highly rated in 32 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
25
conditions
Dr. Reem Karmali
Hematology | Oncology
Expertise in
25
conditions
Dr. Reem Karmali
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reem Karmali is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Karmali has been practicing medicine for over 19 years is highly rated in 25 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
18
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Expertise in
18
conditions
Dr. Jessica K. Altman
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jessica Altman is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Altman has been practicing medicine for over 24 years is highly rated in 18 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lorch's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile